OMVOH (Eli Lilly Australia Pty Ltd)
Product name
OMVOH
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
191 (255 working days
Active ingredients
mirikizumab
Registration type
NCE/NBE
Indication
OMVOH is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have had an inadequate response with, lost response to, or were intolerant to conventional therapy or a biological medicine, or have medical contraindications to such therapies.